Aktuellt
SENASTE
Redeye repeats its view on Sedana Medical’s 2024 sales growth target to be conservative, as is demonstrated by the Q1 sales. With a relatively nearing FDA filing (Q1 2025), the US part of the equity story will become more important going forward. In the meantime, we will keep an extra eye on sales in Spain and the UK. We leave our fair value range unchanged.
LÄS MER
